Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients
Jincong Q. Freeman, Sarah P. Shubeck, Frederick M. Howard, Nan Chen, Rita Nanda, Dezheng Huo
Abstract
OncotypeDX and MammaPrint assays have not been validated to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in early-stage breast cancer patients. We analyzed the 2010-2019 National Cancer Database and found that high OncotypeDX recurrence scores or high MammaPrint scores were associated with greater odds of pCR. Our findings suggest that OncotypeDX and MammaPrint testing predict pCR after NACT and could facilitate clinical decision-making between clinicians and patients.
Topics & Concepts
MedicineBreast cancerStage (stratigraphy)OncologyInternal medicineChemotherapyNeoadjuvant therapyComplete responseCancerOdds ratioBiologyPaleontologyBreast Cancer Treatment StudiesCancer Genomics and DiagnosticsBRCA gene mutations in cancer